Elexacaftor/Ivacaftor/tezacaftor/Iron: Alopecia and lack of efficacy: 6 case reports.

In a retrospective cohort study, six patients with cystic fibrosis developed alopecia while receiving therapy with elexacaftor/ivacaftor/tezacaftor. The patients had a history of cystic fibrosis and received either Trikafta or lexacaftor/ivacaftor/tezacaftor. The duration of alopecia ranged from 6 to 24 months from the start of therapy. Laboratory findings showed low iron levels, low ferritin, high prothrombin time, high transferrin, and one patient tested positive for COVID-19. Treatment with biotin, oral contraceptives, minoxidil, spironolactone, iron supplements, and OTC hair supplements improved alopecia in five patients, but one patient did not respond to iron supplements, indicating lack of efficacy. [Extracted from the article]